Circulating tumor DNA informs response-adapted bladder preservation in muscle invasive bladder cancer: an integrated analysis of the RETAIN trials

Read full text Summarise with VIRAT
Authors: Pooja Ghatalia, Eric A. Ross, Li Zhang, Alexander W. Macfarlane, Matthew R. Zibelman, Fern M. Anari, Philip H. Abbosh, Cameron Herberts, William J. Tester, Patrick Johnston Mille, Tracy Rose, Suzanne Cole
+17 more Samantha K. Cheung, P. Dutta, Shruti Sharma, Adam ElNaggar, Minetta C. Liu, James Ryan Mark, Rosalia Viterbo, E.M. Horwitz, Mark A. Hallman, Andres Correa, Marc Smaldone, Robert Uzzo, David Y.T. Chen, Kerry Campbell, Alexander Kutikov, Elizabeth R. Plimack, Daniel M. Geynisman
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Muscle-invasive bladder cancer (MIBC) is traditionally managed with neoadjuvant chemotherapy followed by radical cystectomy. Although bladder preservation offers substantial quality-of-life advantages, clinically validated biomarkers to guide organ-sparing strategies are lacking. Here, we report results from RETAIN-2, a phase II trial evaluating neoadjuvant AMVAC plus nivolumab followed by response-adapted management, alongside an integrated tumor-informed circulating tumor DNA (ctDNA) analysis spanning 111 patients across RETAIN-1 and RETAIN-2. Whereas prior ctDNA studies in MIBC have been limited to cystectomy- or chemoradiation-based paradigms and largely limited to binary assessment at discrete timepoints, this integrated analysis uniquely captures longitudinal ctDNA dynamics in patients forgoing any immediate definitive local therapy, representing the largest prospective ctDNA dataset in any bladder-preservation trial. RETAIN-2 met its primary endpoint, with 70% of patients metastasis-free at 2 years. The Kaplan–Meier analysis estimated 2-year MFS was 83.5% and 68% of active surveillance patients remained metastasis-free with intact, non-irradiated bladders. Baseline and post-treatment ctDNA positivity were strongly associated with inferior metastasis-free and overall survival. Critically, ctDNA-negative patients managed with active surveillance had outcomes comparable to those undergoing cystectomy (24-month MFS 91% vs. 84%; OS 97% vs. 89%), providing the first prospective evidence that ctDNA negativity can identify patients who safely avoid radical cystectomy without compromising metastatic control. Importantly, plasma ctDNA reflected systemic metastatic risk rather than intravesical disease burden, underscoring the need for complementary bladder-directed surveillance. These results establish ctDNA as a clinically actionable biomarker for response-adapted organ preservation in MIBC. Trial registration number: NCT02710734

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Genomics and Diagnostics Urinary and Genital Oncology Studies

Publication details

Journal / source
Research Square
Publication date
30 March 2026
Language
EN
Document type
Preprint